Lido Advisors LLC Acquires New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Lido Advisors LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rhumbline Advisers raised its stake in Halozyme Therapeutics by 6.6% in the 3rd quarter. Rhumbline Advisers now owns 143,342 shares of the biopharmaceutical company’s stock valued at $2,490,000 after purchasing an additional 8,903 shares during the last quarter. Granite Investment Partners LLC raised its stake in Halozyme Therapeutics by 44.7% in the 3rd quarter. Granite Investment Partners LLC now owns 818,505 shares of the biopharmaceutical company’s stock valued at $14,217,000 after purchasing an additional 252,998 shares during the last quarter. Legal & General Group Plc grew its holdings in Halozyme Therapeutics by 36.4% in the 3rd quarter. Legal & General Group Plc now owns 60,157 shares of the biopharmaceutical company’s stock valued at $1,045,000 after buying an additional 16,041 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Halozyme Therapeutics by 7.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,868,670 shares of the biopharmaceutical company’s stock valued at $49,915,000 after buying an additional 191,476 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in Halozyme Therapeutics by 11.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 570,513 shares of the biopharmaceutical company’s stock valued at $9,910,000 after buying an additional 58,707 shares in the last quarter. Hedge funds and other institutional investors own 85.64% of the company’s stock.

How to Become a New Pot Stock Millionaire

HALO stock traded down $0.55 during midday trading on Friday, hitting $18.94. 581,125 shares of the stock were exchanged, compared to its average volume of 994,772. The stock has a market cap of $2,722.27, a PE ratio of 42.09 and a beta of 1.87. Halozyme Therapeutics, Inc. has a fifty-two week low of $11.41 and a fifty-two week high of $21.48. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.85 and a current ratio of 3.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.27. Halozyme Therapeutics had a return on equity of 89.83% and a net margin of 19.89%. The company had revenue of $189.60 million during the quarter, compared to analysts’ expectations of $173.11 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. The business’s revenue for the quarter was up 386.2% compared to the same quarter last year. equities research analysts predict that Halozyme Therapeutics, Inc. will post -0.82 earnings per share for the current year.

HALO has been the subject of several analyst reports. TheStreet upgraded Halozyme Therapeutics from a “d” rating to a “b-” rating in a report on Friday, March 16th. BidaskClub raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, February 24th. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Tuesday, December 12th. Canaccord Genuity increased their price target on Halozyme Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Finally, Deutsche Bank set a $21.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $19.89.

COPYRIGHT VIOLATION NOTICE: “Lido Advisors LLC Acquires New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/10000-shares-in-halozyme-therapeutics-inc-halo-purchased-by-lido-advisors-llc.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply